Duloxetine in the treatment of major depressive disorder

(1957) Views  (521) Full article downloads

Author: David J Goldstein

Published Date June 2007 Volume 2007:3(2) Pages 193 - 209

DOI: http://dx.doi.org/10.2147/NDT.S

David J Goldstein

Department of Toxicology and Pharmacology, Indiana University School of Medicine, and PRN Consulting, Indianapolis, IN, USA

Abstract: Since depression impacts all body systems, antidepressant treatments should relieve both the emotional and physical symptoms of depression. Duloxetine demonstrated antidepressant efficacy at a dose of 60 mg qd in two placebo-controlled, randomized, double-blind studies and significantly improved remission rates compared with placebo. Duloxetine-treated patients had significant reduction in severity of the symptoms of depression as assessed by the HAM-D17, anxious symptoms as measured by the HAM-A and quality of life measures compared to placebo. Duloxetine also improved somatic symptoms, particularly painful symptoms which may have contributed to significantly improved remission rates compared to placebo. Approximately 10% of the 1139 patients with major depressive disorder in placebo-controlled trials discontinued treatment due to an adverse event, compared to 4% of the 777 patients receiving placebo. In addition to nausea (1.4% incidence), which was the most common reason for discontinuation, dizziness, somnolence, and fatigue were the most common AEs reported as reasons for discontinuation and all were considered drug-related. Duloxetine treatment lacks effects on ECG, increases heart rate, and has little effect on blood pressure or weight.

Keywords: duloxetine, depression, antidepressant, SNRI, quality of life, pain.